Imatinib Zentiva

Imatinib, the active ingredient in Imatinib Zentiva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is employed to treat chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, targeting malignant cells that express the BCR‑ABL fusion protein, approved in the European Union and widely used in oncology practice.

GNH USA supplies Imatinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide and research institutions, with a focus on quality assurance and regulatory compliance.

Imatinib acts on the BCR‑ABL tyrosine kinase pathway and is indicated for several hematologic and solid‑tumor indications.

Chronic Myeloid Leukemia: reduces leukemic cell proliferation and improves long‑term survival. Gastrointestinal Stromal Tumor: inhibits tumor growth and delays disease progression in patients with KIT or PDGFRA mutations. Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia: achieves remission by targeting BCR‑ABL‑positive blasts.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Peripheral edema - Fatigue - Diarrhea

Serious or Rare Side Effects: - Neutropenia - Hepatotoxicity - Severe skin reactions such as Stevens‑Johnson syndrome

When prescribing Imatinib, clinicians should observe several precautionary measures to ensure patient safety. - Monitor blood counts: perform regular complete blood count assessments to detect cytopenias. - Assess liver function: evaluate hepatic enzymes before and during therapy. - Evaluate cardiac status: check for pre‑existing heart failure or reduced ejection fraction. - Avoid in patients with known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in renal impairment: adjust monitoring as renal clearance is limited. - Store at below 25°C: keep in the original pack, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib levels and risk serious toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can lower imatinib exposure and reduce efficacy. - Concomitant use with antacids containing aluminum or magnesium: may impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 substrate drugs (e.g., midazolam, cyclosporine): imatinib may increase their concentrations; monitor therapeutic effect. - Diuretics (e.g., hydrochlorothiazide): may enhance fluid retention; observe for edema. - Live vaccines: immunosuppression from imatinib can diminish vaccine efficacy; consider timing.